The RADAR-AD project, launched in January 2019 with three years duration, is expected to bring such technologies closer to pharmaceutical practice. The aim of the RADAR-AD (Remote Assessment of Disease and Relapse in Alzheimer’s Disease) is to develop and validate technologically advanced and sensitive measurements of the daily problems of people who are at the initial stage of AD (e.g., Mild Cognitive Impairment). To achieve this, RADAR-AD will work in close collaboration with patient organizations and regulatory authorities to select and integrate the most relevant devices available in order to measure daily function in a timely manner. Overall, the assessment of the proposed technology will be carried out across Europe, involving around 220 people from all stages of the AD continuum.

The project consortium consists of 17 European organizations: academic, such as King's College London, Oxford University and the Karolinska Institute, industrial, such as Lygature, The Hyve, Software AG, and the non-governmental organization Alzheimer Europe. Most notable, pharmaceutical companies, which include Janssen, Novartis, Johnson & Johnson, Takeda and Lilly, are also involved and co-finance the project, through the European Federation of Pharmaceutical Industries and Associations (EFPIA). Coordination has been undertaken by King's College London together with EFPIA Janssen and Novartis. The Information Technologies Institute (ITI) of the Center for Research and Technology Hellas (CERTH), and in particular the Multimedia Knowledge and Social Networks Laboratory (MKLab), will significantly contribute to RADAR-AD through its many years of experience in the field of e-health, diagnosis, remote monitoring, assistive solutions and smart systems and the coordination of several health-related projects (such as www.demcare.eu).

Specifically, within RADAR-AD, CERTH-ITI will host 10 patients to stay at the “ITI-Smart Home”, a real living environment with embedded sensors and smart devices. Through this pilot, we will have the opportunity to investigate various behavioral patterns, difficulties occurring within the AD spectrum, multiple biological functions, daily functionality problems and various aspects of deterioration in people with AD. This particular pilot is one of the three of the project and considered as a pioneering assessment of people with AD at a realistic home-like research environment. More specifically, it is expected to play a pivotal role in the final choice of the technology and equipment package of the project.

Consortium
1 KING'S COLLEGE LONDON
2 STICHTING LYGATURE
3 STICHTING VUMC
4 THE HYVE BV
5 THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
6 KAROLINSKA INSTITUTET
7 AGENTSCHAP COLLEGE TER BEOORDELING VAN GENEESMIDDELEN
8 FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.
9 ALZHEIMER EUROPE
10 JANSSEN PHARMACEUTICA NV
11 TAKEDA DEVELOPMENT CENTRE EUROPE LTD.
12 NOVARTIS PHARMA AG
13 NOKIA BELL
14 Eli Lilly and Company Limited
15 SOFTWARE AG
16 ETHNIKO KENTRO EREVNAS KAI TECHNOLOGIKIS ANAPTYXIS
17 Altoida AG

Contact
Dr. Ioannis Kompatsiaris
Building A - Office 2.09
Information Technologies Institute
Centre of Research & Technology - Hellas
6th km Harilaou - Thermi, 57001, Thessaloniki, Greece
Tel.: +30 2311 257774
Fax: +30 2310 474128
Email: ikom@iti.gr
Url: http://mklab.iti.gr